Skip to Content
Morningstar

Baxter International Inc BAX Stock Quote

Morningstar Rating
| Rating as of

NYSE: BAX

Morningstar‘s Stock Analysis BAX

Valuation
Currency in —
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Baxter's Near-Term Outlook Roiled by Supply Chain Pressures

Julie Utterback Senior Equity Analyst

Business Strategy and Outlook

| Julie Utterback |

Following the spinoff of Baxalta in mid-2015, Baxter's new management team has focused on increasing efficiencies and innovating in medical products. That focus has resulted in much-improved profitability and cash flow generation since then. In the intermediate term, the company aims for mid-single-digit sales growth primarily through new product launches and for double-digit adjusted earnings per share and free cash flow growth compounded annually. Acquisitions, like the recent combination with Hillrom (medical equipment like hospital beds with digital connection capabilities), could add to those prospects.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BAX

More

Company Profile BAX

Business Description

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. The company offers contract manufacturing services to pharmaceutical companies. The Hillrom transaction has added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's 2021 revenue came from more digitally connected offerings like its smart beds and Voalte medical communications app.

Contact
One Baxter Parkway
Deerfield, IL, 60015
Sector Healthcare
Industry Medical Instruments & Supplies
Employees 60,000

Related Articles BAX

Market Update

6 Undervalued Stocks With Low Beta

Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
Jakir Hossain
Our Picks

Is It Time to Sell These 5 Stocks?

These names suffered double-digit losses in October. Should you hold on?
Susan Dziubinski
Stock Strategist

Home Dialysis to Benefit These Undervalued Providers

DaVita and Fresenius are best positioned to capture the incremental profits from home therapy.
Jake Strole
Advisor Insights

Enduring Philosophy

At Aristotle, the emphasis is on long-term ownership.
Laura Lallos
US Videos

Friday Five: Time to Tune In to Media Stocks

Overblown concerns over cable cord-cutters could be opening up opportunities in the media sector. Plus, Ackman's sweet tooth for Mondelez, Priceline still attractive, and more.
Jason Stipp
Stock Strategist

Biogen's Drop Looks Like Overreaction

We've lowered our fair value estimate, but the shares remain attractive.
Karen Andersen
Stock Strategist

Competition Rising for Baxalta

The newly independent firm still has a narrow moat, however.
Karen Andersen
Stock Strategist

Baxter's Headwinds Mostly Temporary

The company faces near-term challenges after the split, but we still like its moat.
Michael Waterhouse

Related News BAX

More

FAQs for Baxter International Inc Stock

Yes. BAX has a forward dividend yield of 2.20%. See BAX’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

BAX’s market cap is 26.41 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

BAX’s stock style is Mid Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

BAX’s price/sales is 1.80.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

BAX’s price/forward earnings is 14.27.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

BAX’s price/book is 4.79.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See BAX’s valuation ratios compared to the Market Index.

BAX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare BAX’s historical performance against its industry peers and the overall market.